BioNTech SE is a German biopharmaceutical company based in Mainz that develops immunotherapies and vaccines, with a core focus on messenger RNA (mRNA) technologies. The company conducts research and commercialization in infectious diseases and oncology, and co-developed the first widely authorized mRNA COVID-19 vaccine with Pfizer.
BioNTech’s platforms include mRNA design and delivery using lipid nanoparticle formulations, individualized neoantigen cancer vaccines, engineered cell therapies (CAR-T/TCR), and recombinant antibodies. It operates GMP manufacturing for mRNA, plasmid DNA, and sterile drug product, supported by process and analytical development. The company advances programs from discovery through late-stage clinical trials, often in collaboration with academic and industry partners, and relies on specialized raw materials and excipients from the chemical supply chain. BioNTech is listed on Nasdaq (BNTX).